| Literature DB >> 18166137 |
Ze Tian1, Jianyong Si, Qi Chang, Liang Zhou, Shilin Chen, Peigen Xiao, Erxi Wu.
Abstract
BACKGROUND: Medicinal plant is a main source of cancer drug development. Some of the cycloartane triterpenoids isolated from the aerial part of Cimicifuga dahurica showed cytotoxicity in several cancer cell lines. It is of great interest to examine the antiproliferative activity and mechanisms of total triterpenoid glycosides of C. dahurica and therefore might eventually be useful in the prevention or treatment of Hepatoma.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18166137 PMCID: PMC2222640 DOI: 10.1186/1471-2407-7-237
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Triterpene constituents from C. dahurica Thurez Maxim
| 1 | Cimilactone A [12β-acetoxy-3β-β-D-xylopyrano-syloxy-24, 25, 26, 27-tetranor-9,19-cyclolanost-16, 23 -lactone] |
| 2 | Cimilactone B [12β-acetoxy-3β-β-D-xylopyranosyloxy-24, 25, 26, 27-tetranor-9,19-cyclolanost-7-ene – 16, 23-lactone] |
| 3 | Cimidahuside C [12β-acetoxy- 15-oxo-shengmanol-3-O-β-D-xylopyranoside] |
| 4 | Cimidahuside D [12β-acetoxy- 15-oxo-7, 8-didehydroshengmanol- 3-O-β-D-xylopyranoside] |
| 5 | Cimidahuside E [(20R, 24R)-24, 25-epoxy-3β-(β-D-xylopyranosyloxy)-9,19-cyclolanost-7-ene-16, 23-dione] |
| 6 | Cimidahuside F [(20R, 24R)-24, 25-epoxy-15a-hydroxy-3β-(β-D-xylopyranosyloxy)-9,19-cyclolanost-7-ene-16,23-dione] |
| 7 | Cimidahuside G [(23R,24S)-15- oxo-16-enol-9,19-cyclolanostane-3-O-β-D-xylopyranoside] |
| 8 | Cimidahuside H [(23R,24S)-15- oxo-16-enol-9, 19-cyclolanostane -7-ene-3-O-β-D-xylopyranoside] |
| 9 | Cimidahuside I [(23R, 24S)- 12β-acetoxy-15-oxo-16-enol-9,19-cyclolanostane-3-O-β-D-xylopyranoside] |
| 10 | Cimidahuside J [(23R,24S)- 12β-acetoxy-15-oxo-16-enol-9, 19-cyclolanostane-7-ene-3-O-β-D-xylopyranosid e] |
| 14 | (20R, 24R)-11β,24,25-trihydroxy -3-β-(β-D-xylopyranosyloxy)- 9,19-cyclolanost-7-ene-16,23- dione |
| 15 | 25-anhydrocimigenol-3-O-β-D-xylopyranoside |
| 16 | 24-epi-7,8-didehydrocimigenol -3-O-β-D-xylopyranoside |
| 17 | cimigenol-3-O-β-D- xylopyranoside |
| 18 | 7,8-didehydrocimigenol-3-O-β-D-xylopyranoside |
| 19 | 25-O-methylcimigenol-3-O-β-D- xylopyranoside |
| 20 | 15a-hydroxycimicidol-3-O-β-D-xylopyranoside |
| 21 | 7β-hydroxycimigenol-3-O-β-D-xylopyranoside |
| 22 | 12β-hydroxycimigenol-3-O-β-D-xylopyranoside |
| 23 | 24-O-acetyl-7, 8-didehydrocimigenol-3-O-β-D-xylopyranoside |
| 24 | 24-O-acetylcimigenol-3-O-β-D-xylopyranoside |
| 25 | 25-O-methyl-24-O-acetylcimigenol-3-O-β-D-xylopyranoside |
| 26 | 12β-O-acetylcimiaceroside A |
| 27 | 12β-O-acetylcimiaceroside B |
| 28 | cimiaceroside A |
| 29 | cimiaceroside B |
Figure 1Cytotoxic activity of TGA in HepG2 cells and normal mouse hepatocytes. The cells were treated with vehicle or TGA from 7.8125 μg/ml to 250 μg/ml. Figure shown represents one of three independent experiments.
Figure 2Morphological changes of HepG2 cell line in response to TGA at 50 μg/ml for different time points. 1–4, HepG2-cells treated with TGA at 50 μg/ml for 0, 12, 24 and 48 h, respectively.
Figure 3Flow cytometric analysis of HepG2 cells treated by TGA for 24 h. 1, Control; 2–4, HepG2 cells treatment with 25, 50 and 100 μg/ml TGA for 24 h.
Figure 4Cell cycle distributions of HepG2 cells treated with TGA at different times and dosages. Cells were stained with PI and analyzed by flow cytometry. 1–3, HepG2 control for 12, 24 and 48 h respectively; 4–6, HepG2 cells treated with TGA at 50 μg/ml for 12, 24 and 48 h respectively. 7–8, HepG2 cells treated with TGA at 25 and 100 μg/ml for 48 h. Figures shown are one of three representative experiments.
Figure 5Regulation of Bax and Bcl-2 protein expression on HepG2 cells by TGA. Cellular lysate protein (50 μg/lane) was loaded on a 10% SDS-polyacrylamide gel, electrophoresed, and subsequently transferred onto nitrocellulose. Immunoblots were detected with antibody specific for Bcl-2 and Bax. Lysates were from HepG2 cells treated with 50 μg/ml TGA for 0, 12, 24 and 48 h, respectively. The ratio of Bax/Bcl-2 was analyzed by pImage.
Tumor growth inhibitory effect of TGA on H22 cells (mean ± SD, n = 10)
| Samples | Dosage (mg/kg) | Tumor weight (g) | Growth inhibition % |
| Control | - | 3.28 ± 1.27 | |
| Cyclophosphamide | 15 | 0.93 ± 0.45a | 71.67 |
| TGA | 200 | 1.64 ± 0.76b | 49.92 |
| TGA | 100 | 1.99 ± 0.82c | 39.30 |
| TGA | 50 | 2.06 ± 1.30c | 36.98 |
ap < 0.001, bP < 0.01, cp < 0.05 vs control.